• Home
  • Search Results
  • Estimation of benchmark dose for micronucleus occurrence in Chinese vinyl chloride-exposed workers.

Estimation of benchmark dose for micronucleus occurrence in Chinese vinyl chloride-exposed workers.

International journal of hygiene and environmental health (2012-03-20)
Qi Wang, Hong-Shan Tan, Xiao-Ming Ma, Yuan Sun, Nan-Nan Feng, Li-Fang Zhou, Yun-Jie Ye, Yi-Liang Zhu, Yong-Liang Li, Paul W Brandt-Rauf, Nai-Jun Tang, Zhao-Lin Xia
ABSTRACT

In this study, we estimated the possibility of using benchmark dose (BMD) to assess the dose-response relationship between vinyl chloride monomer (VCM) exposure and chromosome damage. A group of 317 workers occupationally exposed to vinyl chloride monomer and 166 normal, unexposed control in Shandong Province northern China were examined for chromosomal damage in peripheral blood lymphocytes (PBL) using the cytokinesis-blocked micronucleus (CB-MN) assay of DNA damage. The exposed group (3.47 ± 2.65)‰ showed higher micronucleus frequency than the control (1.60 ± 1.30)‰ (P < 0.01). Occupational exposure level based on micronucleus occurrence in all individuals was analyzed with benchmark dose (BMD) methods. The benchmark dose lower limit of a one-sided 95% confidence interval (BMDL) for 10% excess risk was also determined. Results showed a dose-response relationship between cumulative exposure and MN frequency, and a BMDL of 0.54 mg/m3 and 0.23 mg/m3 for males and females, respectively. Female workers were more susceptible to MN damage than male workers.

MATERIALS
Product Number
Brand
Product Description

Supelco
Vinyl chloride solution, certified reference material, 2000 μg/mL in methanol
Supelco
Vinyl chloride solution, 200 μg/mL in methanol, analytical standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.